Working together to accelerate life science research
We have collaborated closely with GSK on the development of dragonfly discovery to deeply understand the needs of the scientists involved in early stage drug discovery. By working together with the team at GSK we have developed an instrument that helps them achieve their goal of reducing drug discovery cycle times. The combination of innovative technology and the incorporation of specific hardware and software features requested by our collaborators ensures that dragonfly discovery not only significantly reduces assay development time, but also enables more seamless transition from assay development in to the screening phase. Additionally, it permits them to routinely deploy design of experiment (DoE) as part of assay development, particularly beneficial for complex cellular assays.
"So far it's been an incredibly fruitful collaboration...working together in collaboration we can make sure that we end up with a technology that really addresses our needs..." Melanie Leveridge, Head Screening, Profiling & Mechanistic Biology, GSK.
Dart NeuroScience LLC (DNS) was a pharmaceutical company focusing on the discovery and development of innovative drugs for memory disorders. DNS made the radical decision to create more drug compounds in-house thereby protecting their own IP. To succeed in this task, which would increase the size of their compound collection to one million compounds, many challenges needed to be overcome. We embraced the challenge and successfully supplied DNS with all the technology and tools to optimise their workflow in 3 easy steps; storing their compounds in high-density, automated stores, processing the tubes using automated retrieval and transport system and automating the creation of assay ready plates.
"We know that SPT Labtech’s comPOUND-comPILER platform will provide the exceptional long-term storage and tube-to-plate processing capabilities that we require." Jose Quiroz, Manager of Laboratory Systems, Dart NeuroScience LLC
Established in 1998 as a global web-based company providing high quality reagents for both academic research and the drug development industry, Abcam grew rapidly, expanding its antibody repertoire and throughput. As space became limited, they soon needed an automated, reliable, low cost, small footprint solution to store valuable antibody stocks. This was to replace costly, unreliable and large traditional -20ºC and -80ºC laboratory freezers. Today Abcam’s twelve locations are located in the world’s leading life science research hubs, selling to more than 100 countries and it was admitted to AIM in 2005 (AIM: ABC). As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. With an extensive stock range and large sample numbers, Abcam need rapid access, robust, secure, efficient sample storage and management.